Pfizer Director James C. Smith Receives Deferred Phantom Stock Compensation

Executive Summary

On September 29, 2026, Pfizer Inc ($PFE) filed a Form 4 on behalf of Director James C. Smith. The report indicates an acquisition of 1,569.585 phantom stock units on September 25, 2026, at an effective price of $28.67 per share, totaling approximately $45,000.

Transaction Details

• Security: Phantom Stock Units (convertible 1:1 into Common Stock or cash)
• Transaction Code: A (Award/Grant)
• Shares/Units Acquired: 1,569.585
• Price per Unit: $28.67
• Total Transaction Value: $45,000.00
• Post-Transaction Holdings: 187,210.086 phantom stock units held directly
• Settlement Terms: Settled in cash or common stock at the director's election following retirement from the Board of Directors.

Market & Trading Significance

This transaction represents routine deferred compensation for board service rather than an open-market purchase or sale. Because it is part of standard director compensation arrangements and non-discretionary equity-linked accrual, it holds low informational significance for broader market sentiment and common equity price trajectory.